P

Paul B. Chapman

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0003-1618-0811

Publishes on Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses. 516 papers and 44k citations.

PubIndex Score98Top 2%How it's scored

516Publications

44kTotal Citations

First publication: 1965First senior author: 1983

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

Top publicationsby citations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011

Cited by 7.7k

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

Héctor Peinado, David Lyden, Maša Alečković et al.|Nature Medicine|2012

Cited by 3.7k

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Paul B. Chapman, Jeffrey A. Sosman et al.|New England Journal of Medicine|2010

Cited by 3.5k

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|The Lancet|2012

Cited by 3k

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, K. B. Nolop, Peter Hirth et al.|Nature|2010

Cited by 1.8k